Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

• Published in: The New England journal of medicine Vol. 389; no. 12; pp. 1069 - 1084
• Main Authors: Kosiborod, Mikhail N., Abildstrøm, Steen Z., Borlaug, Barry A., Butler, Javed, Rasmussen, Søren, Davies, Melanie, Hovingh, G. Kees, Kitzman, Dalane W., Lindegaard, Marie L., Møller, Daniél V., Shah, Sanjiv J., Treppendahl, Marianne B., Verma, Subodh, Abhayaratna, Walter, Ahmed, Fozia Z., Chopra, Vijay, Ezekowitz, Justin, Fu, Michael, Ito, Hiroshi, Lelonek, Małgorzata, Melenovsky, Vojtech, Merkely, Bela, Núñez, Julio, Perna, Eduardo, Schou, Morten, Senni, Michele, Sharma, Kavita, Van der Meer, Peter, von Lewinski, Dirk, Wolf, Dennis, Petrie, Mark C
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 21.09.2023
• Subjects: Antidiabetics; Body weight loss; C-reactive protein; Cardiology; Cardiomyopathy; Clinical Medicine; Clinical Medicine General; Congestive heart failure; Diabetes; Diet; Ejection fraction; Endocrinology; Gastroenterology; Gastrointestinal surgery; Glucagon-Like Peptides - adverse effects; Glucagon-Like Peptides - therapeutic use; Heart Failure; Heart Failure - complications; Heart Failure - drug therapy; Heart Failure - physiopathology; Humans; Intravenous therapy; Nutrition; Obesity; Obesity - complications; Overweight; Patients; Peptides; Placebos; Quality of life; Statistical analysis; Stroke Volume; Weight control
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2306963

In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise function than placebo.